Cytochrome P-450 2B6 Is Responsible for Interindividual Variability of Propofol Hydroxylation by Human Liver Microsomes
- 1 January 2001
- journal article
- research article
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 94 (1) , 110-119
- https://doi.org/10.1097/00000542-200101000-00021
Abstract
Background: Oxidation of propofol to 4-hydroxypropofol represents a significant pathway in the metabolism of this anesthetic agent in humans. The aim of this study was to identify the principal cytochrome P-450 (CYP) isoforms mediating this biotransformation. Methods: Propofol hydroxylation activities and enzyme kinetics were determined using human liver microsomes and cDNA-expressed CYPs. CYP-specific marker activities and CYP2B6 protein content were also quantified in hepatic microsomes for correlational analyses. Finally, inhibitory antibodies were used to ascertain the relative contribution of CYPs to propofol hydroxylation by hepatic microsomes. Results: Propofol hydroxylation by hepatic microsomes showed more than 19-fold variability and was most closely correlated to CYP2B6 protein content (r = 0.904), and the CYP2B6 marker activities, S-mephenytoin N-demethylation (r = 0.919) and bupropion hydroxylation (r = 0.854). High- and intermediate-activity livers demonstrated high-affinity enzyme kinetics (K(m) < 8 microm), whereas low-activity livers displayed low-affinity kinetics (K(m) > 80 microm). All of the CYPs evaluated were capable of hydroxylating propofol; however, CYP2B6 and CYP2C9 were most active. Kinetic analysis indicated that CYP2B6 is a high-affinity (K(m) = 10 +/- 2 microm; mean +/- SE of the estimate), high-capacity enzyme, whereas CYP2C9 is a low-affinity (K(m) = 41 +/- 8 microm), high-capacity enzyme. Furthermore, immunoinhibition showed a greater contribution of CYP2B6 (56 +/- 22% inhibition; mean +/- SD) compared with CYP2C isoforms (16 +/- 7% inhibition) to hepatic microsomal activity. Conclusions: Cytochrome P-450 2B6, and to a lesser extent CYP2C9, contribute to the oxidative metabolism of propofol. However, CYP2B6 is the principal determinant of interindividual variability in the hydroxylation of this drug by human liver microsomes.Keywords
This publication has 23 references indexed in Scilit:
- Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofolBritish Journal of Anaesthesia, 1998
- Quantitation of Propofol Metabolite, 2,6-Diisopropyl-1,4-quinol, by Gas Chromatography-Mass SpectrometryAnalytical Letters, 1997
- Biotransformation of Chlorzoxazone by Heptatic Microsomes from Humans and Ten Other Mammalian SpeciesBiopharmaceutics & Drug Disposition, 1997
- Role of cytochrome P450 2C9 and an allelic variant in the 4′-hydroxylation of (R)- and (S)-flurbiprofenBiochemical Pharmacology, 1995
- Use of proton nmr spectroscopy to measure propofol metabolites in the urine of the female Caucasian patientXenobiotica, 1994
- The expression of UDP-glucuronosyltransferases of the UGT1 family in human liver and kidney and in response to drugsBiochemical Pharmacology, 1993
- Species differences in blood profiles, metabolism and excretion of14C-propofol after intravenous dosing to rat, dog and rabbitXenobiotica, 1991
- Disposition in male volunteers of a subanaesthetic intravenous dose of an oil in water emulsion of14C-propofolXenobiotica, 1988
- High-performance liquid chromatographic determination and preliminary pharmacokinetics of propofol and its metabolites in human plasma and urineJournal of Chromatography B: Biomedical Sciences and Applications, 1987
- Determination of Bupropion and Its Major Basic Metabolites in Plasma by Liquid Chromatography With Dual-Wavelength Ultraviolet DetectionJournal of Pharmaceutical Sciences, 1984